Randomizing 408 patients with symptomatic (current or recent NYHA class III) HFrEF with a LVEF ≤35%, BeAT-HF demonstrated a significant improvement in functional status and MLWHFQ QoL scores, 6-minute walk distance (6MWD), and a reduction in NT-proBNP levels at 6 month follow-up in the patients randomized to BAT and medical therapy arm versus control (medical therapy alone).45 This evidence concerns the gene NPPB and hydrops fetalis.